Total Payments
$76,364
2024 Payments
$11,580
Companies
15
Transactions
58
Medicare Patients
856
Medicare Billing
$153,521
Payment Breakdown by Category
Consulting$72,915 (95.5%)
Travel$1,725 (2.3%)
Food & Beverage$1,724 (2.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $72,915 | 11 | 95.5% |
| Travel and Lodging | $1,725 | 11 | 2.3% |
| Food and Beverage | $1,724 | 36 | 2.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Immucor, Inc. | $49,500 | 3 | $0 (2023) |
| Otsuka America Pharmaceutical, Inc. | $8,945 | 9 | $0 (2024) |
| Mallinckrodt Enterprises LLC | $5,032 | 8 | $0 (2019) |
| Takeda Pharmaceuticals U.S.A., Inc. | $4,023 | 3 | $0 (2022) |
| Gilead Sciences, Inc. | $3,202 | 7 | $0 (2019) |
| CALLIDITAS THERAPEUTICS US INC. | $2,528 | 2 | $0 (2024) |
| Horizon Pharma plc | $1,350 | 1 | $0 (2017) |
| GlaxoSmithKline, LLC. | $750.00 | 1 | $0 (2017) |
| AbbVie Inc. | $336.82 | 10 | $0 (2021) |
| Novartis Pharmaceuticals Corporation | $289.68 | 3 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $11,580 | 11 | Otsuka America Pharmaceutical, Inc. ($8,945) |
| 2023 | $8,779 | 5 | Immucor, Inc. ($8,500) |
| 2022 | $1,523 | 2 | Immucor, Inc. ($1,500) |
| 2021 | $43,667 | 9 | Immucor, Inc. ($39,500) |
| 2020 | $106.08 | 4 | AbbVie Inc. ($106.08) |
| 2019 | $7,667 | 15 | Mallinckrodt Enterprises LLC ($4,262) |
| 2018 | $790.28 | 7 | Mallinckrodt LLC ($769.71) |
| 2017 | $2,252 | 5 | Horizon Pharma plc ($1,350) |
All Payment Transactions
58 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/13/2024 | Otsuka America Pharmaceutical, Inc. | — | Consulting Fee | Cash or cash equivalent | $7,665.00 | General |
| 12/13/2024 | Otsuka America Pharmaceutical, Inc. | — | Travel and Lodging | Cash or cash equivalent | $123.57 | General |
| 12/13/2024 | Otsuka America Pharmaceutical, Inc. | — | Travel and Lodging | Cash or cash equivalent | $77.88 | General |
| 12/13/2024 | Otsuka America Pharmaceutical, Inc. | — | Travel and Lodging | Cash or cash equivalent | $8.16 | General |
| 11/14/2024 | Otsuka America Pharmaceutical, Inc. | — | Food and Beverage | In-kind items and services | $50.41 | General |
| 11/14/2024 | Otsuka America Pharmaceutical, Inc. | — | Food and Beverage | In-kind items and services | $47.02 | General |
| 11/13/2024 | Otsuka America Pharmaceutical, Inc. | — | Food and Beverage | In-kind items and services | $144.21 | General |
| 11/12/2024 | Otsuka America Pharmaceutical, Inc. | — | Travel and Lodging | In-kind items and services | $562.00 | General |
| 11/12/2024 | Otsuka America Pharmaceutical, Inc. | — | Travel and Lodging | In-kind items and services | $266.46 | General |
| 06/04/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Consulting Fee | Cash or cash equivalent | $2,500.00 | General |
| Category: Nephrology | ||||||
| 06/03/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $134.95 | General |
| 07/13/2023 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $31.76 | General |
| 06/04/2023 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $122.97 | General |
| 03/17/2023 | Immucor, Inc. | — | Consulting Fee | Cash or cash equivalent | $8,500.00 | General |
| 03/06/2023 | Calliditas Therapeutics US Inc. | TARPEYO (Drug) | Food and Beverage | In-kind items and services | $27.64 | General |
| Category: Nephrology | ||||||
| 01/30/2023 | SANOFI-AVENTIS U.S. LLC | THYMOGLOBULIN (Biological) | Food and Beverage | In-kind items and services | $97.08 | General |
| Category: Oncology | ||||||
| 06/24/2022 | Immucor, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| 05/18/2022 | Takeda Pharmaceuticals U.S.A., Inc. | LIVTENCITY (Drug) | Food and Beverage | In-kind items and services | $22.94 | General |
| Category: IMMUNOLOGY | ||||||
| 12/15/2021 | Immucor, Inc. | — | Consulting Fee | Cash or cash equivalent | $39,500.00 | General |
| 10/01/2021 | AbbVie Inc. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $28.52 | General |
| Category: VIROLOGY | ||||||
| 09/03/2021 | AbbVie Inc. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $29.11 | General |
| Category: VIROLOGY | ||||||
| 06/16/2021 | AbbVie Inc. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $29.77 | General |
| Category: VIROLOGY | ||||||
| 06/11/2021 | Veloxis Pharmaceuticals, Inc. | Envarsus (Drug) | Food and Beverage | In-kind items and services | $19.73 | General |
| Category: Immunosuppresant | ||||||
| 05/31/2021 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| 05/31/2021 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 192 | 415 | $255,947 | $39,646 |
| 2022 | 8 | 257 | 485 | $302,110 | $44,194 |
| 2021 | 7 | 211 | 479 | $283,656 | $43,524 |
| 2020 | 7 | 196 | 351 | $171,217 | $26,157 |
Total Patients
856
Total Services
1,730
Medicare Billing
$153,521
Procedure Codes
28
All Medicare Procedures & Services
28 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 74 | 195 | $98,475 | $16,127 | 16.4% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 41 | 124 | $79,970 | $13,488 | 16.9% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 23 | 23 | $26,447 | $2,799 | 10.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 24 | 39 | $20,865 | $2,752 | 13.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 18 | 22 | $17,050 | $2,667 | 15.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 12 | 12 | $13,140 | $1,813 | 13.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 81 | 185 | $93,425 | $16,259 | 17.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 47 | 123 | $70,725 | $11,549 | 16.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 40 | 70 | $37,450 | $4,582 | 12.2% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 34 | 37 | $42,460 | $4,285 | 10.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 20 | 27 | $18,360 | $3,813 | 20.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 11 | 11 | $12,735 | $1,953 | 15.3% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2022 | 11 | 19 | $22,990 | $1,307 | 5.7% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Facility | 2022 | 13 | 13 | $3,965 | $445.44 | 11.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 91 | 252 | $123,660 | $21,195 | 17.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 35 | 101 | $54,795 | $9,792 | 17.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 26 | 56 | $29,790 | $3,784 | 12.7% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 20 | 21 | $24,147 | $2,707 | 11.2% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 12 | 13 | $16,184 | $2,450 | 15.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 16 | 16 | $10,880 | $2,233 | 20.5% |
| 90935 | Hemodialysis procedure with one physician evaluation | Facility | 2021 | 11 | 20 | $24,200 | $1,362 | 5.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 76 | 157 | $69,865 | $10,411 | 14.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 21 | 63 | $31,185 | $6,135 | 19.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 32 | 62 | $27,900 | $4,048 | 14.5% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 22 | 22 | $25,042 | $2,805 | 11.2% |
About Dr. Enver Akalin, M.D
Dr. Enver Akalin, M.D is a Nephrology healthcare provider based in Bronx, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/02/2006. The National Provider Identifier (NPI) number assigned to this provider is 1407885205.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Enver Akalin, M.D has received a total of $76,364 in payments from pharmaceutical and medical device companies, with $11,580 received in 2024. These payments were reported across 58 transactions from 15 companies. The most common payment nature is "Consulting Fee" ($72,915).
As a Medicare-enrolled provider, Akalin has provided services to 856 Medicare beneficiaries, totaling 1,730 services with total Medicare billing of $153,521. Data is available for 4 years (2020–2023), covering 28 distinct procedure/service records.
Ad
Practice Information
- Specialty Nephrology
- Location Bronx, NY
- Active Since 07/02/2006
- Last Updated 05/04/2012
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1407885205
Products in Payments
- ACTHAR (Biological) $5,032
- Vemlidy (Drug) $3,202
- TARPEYO (Drug) $2,528
- KRYSTEXXA (Drug) $1,350
- MAVYRET (Drug) $195.84
- SOLIRIS (Drug) $128.30
- THYMOGLOBULIN (Biological) $97.08
- Mavyret (Drug) $83.75
- Envarsus (Drug) $58.92
- Envarsus XR (Drug) $44.03
- THYMOGLOBULIN (Drug) $41.19
- XARELTO (Drug) $39.07
- LIVTENCITY (Drug) $22.94
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nephrology Doctors in Bronx
Dr. Bruce Spinowitz, M.d, M.D
Nephrology — Payments: $510,667
Nephrology $510,667
Joel Neugarten, Md, MD
Nephrology — Payments: $384,806
Nephrology $384,806
John He, Md, MD
Nephrology — Payments: $24,885
Nephrology $24,885
Abdurhman Ahmed, M.d, M.D
Nephrology — Payments: $12,466
Nephrology $12,466
Dr. Suman Reddy, Md, MD
Nephrology — Payments: $7,783
Nephrology $7,783
Mr. Joseph Bonanno, D.o, D.O
Nephrology — Payments: $7,333
Nephrology $7,333